Laboratory for Pharmaceutical Biology, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, Belgium.
Thromb Res. 2012 Oct;130(4):576-85. doi: 10.1016/j.thromres.2012.06.023. Epub 2012 Jul 15.
Plasminogen activator inhibitor-1 (PAI-1) is the primary physiological inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) and is consequently one the most important inhibitors of the plasminogen/plasmin system. PAI-1 attenuates fibrinolysis and increased levels of active PAI-1 have been associated with an increased risk for cardiovascular diseases. PAI-1 knock-out mice as well as PAI-1 overexpressing mice have been generated and characterized to study the role of PAI-1 in vivo. A number of PAI-1 inhibitors have been generated to study the pharmacological effect of PAI-1 inhibition in vitro and in vivo. The current review provides an overview of 1) the biochemical features of PAI-1, 2) the role of PAI-1 in diverse pathologies, 3) the in vitro and in vivo data obtained with PAI-1 inhibitors and 4) the vitronectin, glycosylation and species dependency of PAI-1 inhibition.
纤溶酶原激活物抑制剂-1(PAI-1)是组织型纤溶酶原激活物(t-PA)和尿激酶型纤溶酶原激活物(u-PA)的主要生理性抑制剂,因此也是纤溶酶原/纤溶系统最重要的抑制剂之一。PAI-1 可减弱纤维蛋白溶解,而活性 PAI-1 水平升高与心血管疾病风险增加相关。已经生成并表征了 PAI-1 敲除小鼠和 PAI-1 过表达小鼠,以研究 PAI-1 在体内的作用。已经生成了许多 PAI-1 抑制剂,以研究 PAI-1 抑制在体外和体内的药理作用。本综述提供了 1)PAI-1 的生化特征、2)PAI-1 在多种病理中的作用、3)使用 PAI-1 抑制剂获得的体外和体内数据以及 4)PAI-1 抑制的 vitronectin、糖基化和物种依赖性的概述。